These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32138868)

  • 1. Where is the focus on hepatitis C research after the introduction of DAAs: To Understand, knowledge, prevent or cure hepatitis C?
    Rivas-Estilla AM; Lozano-Sepulveda SA
    Ann Hepatol; 2020; 19(2):119-120. PubMed ID: 32138868
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral hepatitis at a crossroad.
    Lok AS; Pawlotsky JM
    Gastroenterology; 2012 May; 142(6):1261-3. PubMed ID: 22537431
    [No Abstract]   [Full Text] [Related]  

  • 3. The relationship between hepatocellular carcinoma and hepatitis B and C virus.
    Kohli A
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):96-8. PubMed ID: 27057807
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis C virus and hepatocellular carcinoma.
    Colombo M
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Dec; 13(4):519-28. PubMed ID: 10654917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?
    Maida M; Cabibbo G; Cammà C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):307-309. PubMed ID: 29466888
    [No Abstract]   [Full Text] [Related]  

  • 6. Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Hayashi N; Kasahara A
    Oncology; 2002; 62 Suppl 1():87-93. PubMed ID: 11868793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, risk factors, and natural history of hepatocellular carcinoma.
    Montalto G; Cervello M; Giannitrapani L; Dantona F; Terranova A; Castagnetta LA
    Ann N Y Acad Sci; 2002 Jun; 963():13-20. PubMed ID: 12095924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of hepatocellular carcinoma after clearance of hepatitis C virus with interferon therapy.
    Tong MJ; Lai LP; Murakami-Mori K
    West J Med; 1997 Aug; 167(2):103-5. PubMed ID: 9291751
    [No Abstract]   [Full Text] [Related]  

  • 9. [Risk of hepatocellular carcinoma after hepatitis C virus cure with direct-acting antivirals: the next challenges].
    Hamdane N; Baumert TF; Zeisel MB
    Med Sci (Paris); 2018 May; 34(5):391-394. PubMed ID: 29900836
    [No Abstract]   [Full Text] [Related]  

  • 10. [Analysis of related factors for primary hepatic carcinoma caused by chronic hepatitis B and hepatitis C].
    Nie L; Wang XC; Niu JQ; Shang J; Han Y; Xin GJ; Jia G; Li JL; Ding GW; Liu ZF
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jun; 51(6):546-550. PubMed ID: 28592101
    [No Abstract]   [Full Text] [Related]  

  • 11. [Update on hepatitis C virus: its variability and the implications].
    Lunel F; Stuyver L; Brechot C; Maertens G
    Transfus Clin Biol; 1998 Apr; 5(2):147-65. PubMed ID: 9618840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of hepatocellular carcinoma.
    Kew MC
    S Afr J Surg; 2011 Apr; 49(2):50-1, 86. PubMed ID: 21614973
    [No Abstract]   [Full Text] [Related]  

  • 14. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.
    Wirth TC; Manns MP
    Ann Oncol; 2016 Aug; 27(8):1467-74. PubMed ID: 27226385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)].
    Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842
    [No Abstract]   [Full Text] [Related]  

  • 16. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.
    Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixco C; Decaestecker J; de Galocsy C; Janssens F; Van Overbeke L; Van Steenkiste C; D'Heygere F; Cool M; Wuyckens K; Nevens F; Robaeys G
    J Viral Hepat; 2017 Nov; 24(11):976-981. PubMed ID: 28504854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSG consensus statement on management of hepatitis C virus infection--2003.
    Hamid S; Umar M; Alam A; Siddiqui A; Qureshi H; Butt J;
    J Pak Med Assoc; 2004 Mar; 54(3):146-50. PubMed ID: 15129876
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hepatitis C treatment in consideration of the carcinogenic risk and drug-resistant mutations].
    Sakamoto M; Enomoto N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():165-70. PubMed ID: 26845924
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing.
    Fattovich G; Llovet JM
    J Hepatol; 2006 Jun; 44(6):1013-6. PubMed ID: 16678654
    [No Abstract]   [Full Text] [Related]  

  • 20. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.